10 years of historical data (2016–2025) · Healthcare · Biotechnology
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Arcus Biosciences, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $2.6B | $2.6B | $1.3B | $1.4B | $1.5B | $3.0B | $1.4B | $443M | $373M | — | — |
| Enterprise Value | $2.4B | $2.4B | $1.3B | $1.3B | $1.4B | $3.0B | $1.3B | $385M | $302M | — | — |
| P/E Ratio → | -6.19 | — | — | — | — | 57.00 | — | — | — | — | — |
| P/S Ratio | 10.33 | 10.36 | 5.20 | 12.08 | 13.29 | 7.82 | 18.23 | 29.51 | 44.64 | — | — |
| P/B Ratio | 3.47 | 4.06 | 2.77 | 3.06 | 2.27 | 3.56 | 2.83 | 2.70 | 1.59 | — | — |
| P/FCF | — | — | — | — | 3.45 | — | 13.16 | — | — | — | — |
| P/OCF | — | — | — | — | 3.40 | — | 12.79 | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 9.86 | 4.85 | 11.09 | 12.53 | 7.75 | 16.24 | 25.65 | 36.13 | — | — |
| EV / EBITDA | — | — | — | — | — | 51.16 | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | 53.95 | — | — | — | — | — |
| EV / FCF | — | — | — | — | 3.25 | — | 11.72 | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Arcus Biosciences, Inc. earns an operating margin of -156.3%. Operating margins have expanded from -290.6% to -156.3% over the past 3 years, signaling improving operational efficiency. A negative ROE of -63.3% indicates the company is currently destroying shareholder equity.
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | — |
| Operating Margin | -156.3% | -156.3% | -127.9% | -290.6% | -250.0% | 14.1% | -159.0% | -591.4% | -656.8% | -3782.1% | — |
| Net Profit Margin | -142.9% | -142.9% | -109.7% | -262.4% | -238.4% | 13.8% | -157.7% | -564.7% | -593.7% | -3756.7% | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -63.3% | -63.3% | -59.8% | -54.9% | -35.6% | 7.9% | -36.9% | -42.5% | -25.5% | -41.9% | -18.1% |
| ROA | -30.8% | -30.8% | -25.2% | -25.2% | -18.2% | 4.5% | -25.2% | -35.4% | -21.3% | -35.4% | -16.4% |
| ROIC | -64.1% | -64.1% | -66.8% | -55.6% | -30.3% | 7.0% | -41.1% | -49.3% | -37.5% | -89.3% | — |
| ROCE | -42.1% | -42.1% | -36.0% | -33.0% | -21.7% | 5.2% | -29.8% | -40.5% | -25.2% | -37.9% | -17.5% |
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $222M exceeds total debt of $99M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.16 | 0.16 | 0.12 | 0.02 | 0.18 | 0.14 | 0.04 | — | — | — | — |
| Debt / EBITDA | — | — | — | — | — | 2.10 | — | — | — | — | — |
| Net Debt / Equity | — | -0.19 | -0.19 | -0.25 | -0.13 | -0.03 | -0.31 | -0.35 | -0.30 | -0.64 | -0.66 |
| Net Debt / EBITDA | — | — | — | — | — | -0.45 | — | — | — | — | — |
| Debt / FCF | — | — | — | — | -0.20 | — | -1.44 | — | — | — | — |
| Interest Coverage | — | — | -82.50 | -170.00 | -140.00 | — | — | — | — | — | — |
Net cash position: cash ($222M) exceeds total debt ($99M)
Short-term solvency ratios and asset-utilisation metrics
Arcus Biosciences, Inc.'s current ratio of 4.36x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 4.52x to 4.36x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.36 | 4.36 | 4.50 | 4.52 | 5.52 | 7.60 | 6.05 | 8.49 | 15.29 | 13.90 | 17.98 |
| Quick Ratio | 4.36 | 4.36 | 4.50 | 4.52 | 5.52 | 7.60 | 6.05 | 8.49 | 15.29 | 13.90 | 17.98 |
| Cash Ratio | 4.25 | 4.25 | 4.33 | 4.13 | 5.23 | 3.01 | 5.99 | 8.29 | 15.15 | 13.81 | 17.83 |
| Asset Turnover | — | 0.22 | 0.22 | 0.11 | 0.08 | 0.24 | 0.10 | 0.07 | 0.03 | 0.01 | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | 35.37 | 131.03 | 140.13 | 711.72 | 7.95 | 3.21 | 3.63 | 6.46 | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Arcus Biosciences, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | 1.8% | — | — | — | — | — |
| FCF Yield | — | — | — | — | 29.0% | — | 7.6% | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $107M | $90M | $74M | $72M | $74M | $55M | $44M | $35M | $25M | $25M |
Compare RCUS with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
| RCUSYou | $3B | -6.2 | — | — | — | -156.3% | -63.3% | -64.1% | — |
| RVMD | $20B | -17.1 | — | — | — | — | -58.1% | -54.3% | — |
| INCY | $20B | 15.8 | 11.9 | 14.8 | 91.5% | 26.1% | 29.9% | 51.1% | 0.0 |
| GMAB | $18B | 15.4 | 14.9 | 15.1 | 95.4% | 31.1% | 23.0% | 22.2% | 0.1 |
| EXEL | $12B | 15.8 | 13.2 | 13.4 | — | 37.6% | 35.5% | 32.1% | 0.2 |
| IBRX | $10B | -15.8 | — | — | 100.0% | -2334.2% | — | — | — |
| MRUS | $7B | -26.9 | — | — | 37.2% | -753.0% | -41.4% | -74.6% | — |
| CELC | $5B | -39.5 | — | — | — | — | -87.5% | -50.3% | — |
| CGON | $5B | -41.7 | — | — | 100.0% | -10067.3% | -19.2% | -26.3% | — |
| ERAS | $4B | -19.8 | — | — | — | — | -43.7% | -39.2% | — |
| IDYA | $3B | -25.2 | — | — | 97.9% | -72.8% | -10.9% | -12.4% | — |
| Healthcare Median | — | 23.7 | 13.8 | 18.8 | 65.8% | -6.3% | -37.3% | -15.0% | 3.1 |
Peers based on L4 peer group classification. Compare multiple stocks →
Includes 30+ ratios · 10 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how RCUS stacks up against sector leader Revolution Medicines, Inc..
Start ComparisonArcus Biosciences, Inc.'s current P/E ratio is -6.2x. The historical average is 57.0x.
Arcus Biosciences, Inc.'s return on equity (ROE) is -63.3%. The historical average is -37.1%.
Based on historical data, Arcus Biosciences, Inc. is trading at a P/E of -6.2x. Compare with industry peers and growth rates for a complete picture.
Arcus Biosciences, Inc. has -156.3% operating margin.